[go: up one dir, main page]

WO2001044284A3 - Chimeric natriuretic peptides - Google Patents

Chimeric natriuretic peptides Download PDF

Info

Publication number
WO2001044284A3
WO2001044284A3 PCT/US2000/034080 US0034080W WO0144284A3 WO 2001044284 A3 WO2001044284 A3 WO 2001044284A3 US 0034080 W US0034080 W US 0034080W WO 0144284 A3 WO0144284 A3 WO 0144284A3
Authority
WO
WIPO (PCT)
Prior art keywords
natriuretic peptides
chimeric natriuretic
peptides
chimeric
natriuretics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/034080
Other languages
French (fr)
Other versions
WO2001044284A2 (en
Inventor
John Burnett Jr
Ondrej Lisy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Priority to DE60033431T priority Critical patent/DE60033431T2/en
Priority to EP00988092A priority patent/EP1242452B1/en
Priority to CA2395585A priority patent/CA2395585C/en
Priority to JP2001544773A priority patent/JP5031964B2/en
Priority to DK00988092T priority patent/DK1242452T3/en
Priority to AU24339/01A priority patent/AU2433901A/en
Publication of WO2001044284A2 publication Critical patent/WO2001044284A2/en
Publication of WO2001044284A3 publication Critical patent/WO2001044284A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Peptides of Dendroaspis including chimeric peptides thereof, are provided, as well as methods of using the peptides as natriuretics, diuretics, and/or vasodilators.
PCT/US2000/034080 1999-12-17 2000-12-15 Chimeric natriuretic peptides Ceased WO2001044284A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60033431T DE60033431T2 (en) 1999-12-17 2000-12-15 CHIMERIC NATRIURETIC PEPTIDES
EP00988092A EP1242452B1 (en) 1999-12-17 2000-12-15 Chimeric natriuretic peptides
CA2395585A CA2395585C (en) 1999-12-17 2000-12-15 Chimeric natriuretic peptides
JP2001544773A JP5031964B2 (en) 1999-12-17 2000-12-15 Chimeric natriuretic peptide
DK00988092T DK1242452T3 (en) 1999-12-17 2000-12-15 Chimeric natriuretic peptides
AU24339/01A AU2433901A (en) 1999-12-17 2000-12-15 Chimeric natriuretic peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/466,268 1999-12-17
US09/466,268 US6407211B1 (en) 1999-12-17 1999-12-17 Chimeric natriuretic peptides

Publications (2)

Publication Number Publication Date
WO2001044284A2 WO2001044284A2 (en) 2001-06-21
WO2001044284A3 true WO2001044284A3 (en) 2002-01-31

Family

ID=23851133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034080 Ceased WO2001044284A2 (en) 1999-12-17 2000-12-15 Chimeric natriuretic peptides

Country Status (11)

Country Link
US (4) US6407211B1 (en)
EP (1) EP1242452B1 (en)
JP (1) JP5031964B2 (en)
AT (1) ATE353916T1 (en)
AU (1) AU2433901A (en)
CA (1) CA2395585C (en)
DE (1) DE60033431T2 (en)
DK (1) DK1242452T3 (en)
ES (1) ES2282160T3 (en)
PT (1) PT1242452E (en)
WO (1) WO2001044284A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20040063630A1 (en) * 2002-03-18 2004-04-01 Scios, Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
WO2004022579A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Cellular delivery of natriuretic peptides
US7655772B2 (en) * 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
CA2504287A1 (en) * 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
WO2004097368A2 (en) * 2003-04-28 2004-11-11 Ciphergen Biosystems, Inc. Improved immunoassays
EP2308889B1 (en) 2003-06-20 2018-05-23 Mayo Foundation For Medical Education And Research Isoforms of brain natriuretic peptide
GB2403533A (en) 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
US7291501B2 (en) * 2003-07-16 2007-11-06 Abbott Laboratories Stable compositions for measuring human natriuretic peptides
US7445933B2 (en) * 2003-07-16 2008-11-04 Abbott Laboratories, Inc. Stable calibrators or controls for measuring human natriuretic peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005094420A2 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
PT3404102T (en) 2004-04-21 2021-09-16 Alexion Pharma Inc Bone delivery conjugates and method of using same to target proteins to bone
DE602005026014D1 (en) * 2004-07-15 2011-03-03 Univ Queensland PROTEIN-type compounds and applications thereof
AT500800B1 (en) * 2004-09-08 2008-07-15 Biomedica Medizinprodukte Gmbh PROCESS FOR DETERMINING PROBNP
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
DK2510942T3 (en) 2005-04-07 2015-12-14 Cardiorentis Ag Use of natriuretic peptides for the treatment of heart failure
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
US7803901B2 (en) * 2005-09-16 2010-09-28 Mayo Foundation For Medical Education And Research Polypeptides with natriuresis activity
US7795221B2 (en) * 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
AU2007233116B2 (en) 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
WO2007127487A2 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
CN101501067B (en) 2006-08-08 2013-01-16 梅约医学教育与研究基金会 Diuretic and natriuretic polypeptides
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
JP2010502231A (en) * 2006-09-08 2010-01-28 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Aquatic and natriuretic polypeptides lacking vasodilatory action
US20100062984A1 (en) * 2007-01-25 2010-03-11 Rajiv Kumar Fgf-23 polypeptides
KR101581476B1 (en) * 2007-07-20 2015-12-30 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Natriuretic polypeptides
US8357656B2 (en) 2007-09-15 2013-01-22 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-C agonists
US20090110638A1 (en) * 2007-10-24 2009-04-30 California Institute Of Technology Methods using the grueneberg ganglion chemosensory system
WO2009067639A2 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
JP2011522824A (en) * 2008-06-06 2011-08-04 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2334335A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of cd-np peptides
US8642550B2 (en) * 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
WO2010078325A2 (en) * 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
US20120053123A1 (en) * 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
TWI471137B (en) 2009-05-20 2015-02-01 Biomarin Pharm Inc C-type natriuretic peptide variant
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
AU2010274293B9 (en) * 2009-07-23 2013-08-29 Igisu Co., Ltd. Skin external-preparation composition
BR112012004058A2 (en) 2009-08-27 2021-08-17 Kyoko Endo rhinitis therapeutic preparation
WO2012013597A1 (en) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Substances and the use thereof for influencing natriuretic peptide receptors
DE102010032482A1 (en) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen New receptor agonist having renin-suppressing activity, antihypertrophic activity and influence of second messenger cyclic guanosine monophosphate during vasodilation, natriuresis and diuresis, useful to treat e.g. nephrotic syndrome
WO2012019012A1 (en) 2010-08-04 2012-02-09 Idexx Laboratories, Inc. Detection of degradation products of canine nt-probnp
EP2632477A2 (en) 2010-10-29 2013-09-04 Nile Therapeutics, Inc. Methods of treatment with natriuretic peptides
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
JP5261620B2 (en) 2011-01-21 2013-08-14 京子 遠藤 Alopecia treatment
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
AU2012262154B2 (en) 2011-05-31 2016-08-04 Idexx Laboratories, Inc. Detection of degradation products of feline NT-proBNP
US20130244937A1 (en) * 2011-09-02 2013-09-19 Nile Therapeutics, Inc. Chimeric natriuretic peptide compositions and methods of preparation
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013070741A1 (en) * 2011-11-11 2013-05-16 Mayo Foundation For Medical Education And Research Methods and materials for regulating natriuretic polypeptide function
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US20150080844A1 (en) * 2012-04-02 2015-03-19 Medtronic, Inc. Therapy for kidney disease and/or heart failure by intradermal infusion
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US8835601B2 (en) * 2012-12-21 2014-09-16 Mayo Foundation For Medical Education And Research Natriuretic polypeptide delivery systems
NZ710246A (en) * 2013-01-25 2016-11-25 Cardiorentis Ltd Methods of treating cardiovasular indications
CN103159847B (en) * 2013-04-12 2014-05-28 叶亮 Natriuretic peptide, as well as gene and use thereof
WO2014209229A1 (en) * 2013-06-25 2014-12-31 National University Of Singapore Vasodilation peptides and uses thereof
US9863900B2 (en) 2014-01-28 2018-01-09 Transtech Systems, Inc. Planar sensor array for non-destructive evaluation of material using electromagnetic impedance
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
US10161893B2 (en) 2014-08-19 2018-12-25 Transtech Systems, Inc. Characterization of material under test (MUT) with electromagnetic impedance spectroscopy
CN107405390A (en) 2014-12-05 2017-11-28 阿雷克森制药公司 With recombinant basic phosphoric acid enzyme treatment epilepsy
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP3305804A4 (en) 2015-05-29 2018-11-21 Igisu Co., Ltd. Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
CN108350440A (en) 2015-08-17 2018-07-31 阿雷克森制药公司 Manufacture of Alkaline Phosphates
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFICIENT POSOLOGICAL REGIMES FOR NON-SPECIFIC TISSUE ALKALINE ENZYME PHOSPHATASE REPLACEMENT HYPOPHOSPHATASE (TNSALP) THERAPY
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
US11312758B2 (en) 2016-08-18 2022-04-26 National University Of Singapore Peptides with vasodilatory and/or diuretic functions
KR20190129058A (en) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 How to treat hypophosphatase (HPP) in adults and adolescents
JP2021519590A (en) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Glycoprotein production
ES2972119T3 (en) 2018-08-10 2024-06-11 Alexion Pharma Inc Bone healing in implants using alkaline phosphatase
JP7796645B2 (en) 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド Alkaline phosphatase polypeptides and methods of use thereof
BR112023016048A2 (en) 2021-02-12 2023-11-14 Alexion Pharma Inc ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
US12427185B2 (en) 2023-09-05 2025-09-30 E-Star Biotech, LLC Formulations of MANP and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012576A2 (en) * 1997-09-11 1999-03-18 Musc Foundation For Research Development Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
WO2000071576A2 (en) * 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (en) * 1974-03-08 1982-06-04
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4161521A (en) * 1975-08-08 1979-07-17 Merck & Co., Inc. Somatostatin analogs
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (en) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantable dosing device
NO812612L (en) 1980-08-06 1982-02-08 Ferring Pharma Ltd ENZYME inhibitor.
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4757048A (en) * 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US4804650A (en) * 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US5047397A (en) * 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
WO1993002556A1 (en) 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
CA2248140C (en) 1996-03-04 2005-02-01 Ronald P. Mischak Assay and reagents for quantifying hbnp
US5848956A (en) * 1997-03-18 1998-12-15 Grettner; Norman L. Multi-purpose lat sling
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012576A2 (en) * 1997-09-11 1999-03-18 Musc Foundation For Research Development Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
WO2000071576A2 (en) * 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
B C STEIN & R I LEVIN: "Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease", AMERICAN HEART JOURNAL., vol. 135, no. 5(1), May 1998 (1998-05-01), MOSBY- YEAR BOOK INC., ST. LOUIS, MO., US, pages 914 - 923, XP000960390, ISSN: 0002-8703 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LISY, ONDREJ ET AL: "Therapeutic actions of a new synthetic vasoactive and natriuretic peptide dendroaspis natriuretic peptide, in experimental severe congestive heart failure", XP002171379, retrieved from STN Database accession no. 135:14664 CA *
HYPERTENSION (2001), 37(4), 1089-1094, 2001 *
J A SCHIRGER ET AL.: "Presence of Dendroaspis natriuretic peptide-like immunoreactivity on human plasma and its increase during human heart failure", MAYO CLINIC PROCEEDINGS., vol. 74, February 1999 (1999-02-01), MAYO MEDICAL VENTURES, ROCHESTER, MN., US, pages 126 - 130, XP000960384, ISSN: 0025-6196 *
LISY, ONDREJ ET AL: "Renal actions of synthetic Dendroaspis natriuretic peptide", KIDNEY INT. (1999), 56(2), 502-508, 1999, XP002171378 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9441027B2 (en) 2011-08-30 2016-09-13 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9587004B2 (en) 2011-08-30 2017-03-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides

Also Published As

Publication number Publication date
JP2003517005A (en) 2003-05-20
CA2395585A1 (en) 2001-06-21
PT1242452E (en) 2007-05-31
CA2395585C (en) 2014-09-09
US7384917B2 (en) 2008-06-10
US20030069186A1 (en) 2003-04-10
US20090170756A1 (en) 2009-07-02
US6407211B1 (en) 2002-06-18
ES2282160T3 (en) 2007-10-16
DE60033431D1 (en) 2007-03-29
DE60033431T2 (en) 2007-11-29
JP5031964B2 (en) 2012-09-26
US20020082219A1 (en) 2002-06-27
AU2433901A (en) 2001-06-25
EP1242452B1 (en) 2007-02-14
ATE353916T1 (en) 2007-03-15
WO2001044284A2 (en) 2001-06-21
DK1242452T3 (en) 2007-06-11
US7964564B2 (en) 2011-06-21
US6818619B2 (en) 2004-11-16
US20050059600A1 (en) 2005-03-17
EP1242452A2 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
WO2001044284A3 (en) Chimeric natriuretic peptides
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2001075067A8 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
ZA200201806B (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof.
PT1361893E (en) Modified anti-egfr antibodies with reduced immunogenicity
ZA200203293B (en) Method for synthesizing the nucleic acid.
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2002018424A3 (en) Nucleic acids and polypeptides
WO1995006764A3 (en) Oligonucleotides with rna cleavage activity
AU5906699A (en) (neisseria spp.) polypeptide, nucleic acid sequence and uses thereof
WO2002044340A3 (en) Novel nucleic acids and polypeptides
WO2000053841A3 (en) Unsupported flat linoleum structure and method of producing same
ZA992543B (en) Gluten-free beer.
WO2001053453A8 (en) Novel bone marrow nucleic acids and polypeptides
ZA992214B (en) Oligomeric stabilizer mixture.
MXPA03001602A (en) Niobium based capacitor anode.
MXPA02002734A (en) Gluten substitutes.
AP2006003504A0 (en) Outer surface proteins, their genes, and their use.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 544773

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2395585

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000988092

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000988092

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000988092

Country of ref document: EP